Quantitative Site- and Structure-specific N-glycoproteomics Characterization of Differential N-glycosylation in MCF-7/ADR Cancer Stem Cells

Overview

Journal Clin Proteomics

Publisher Biomed Central

Date 2020 Feb 12

PMID 32042278

Citations 12

Authors

Feifei Xu

Yue Wang

Kaijie Xiao

Yechen Hu

Zhixin Tian

Yun Chen

Affiliations

Soon will be listed here.

Abstract

Background: Cancer stem cells (CSCs) are reported to be responsible for tumor initiation, progression, metastasis, and therapy resistance where P-glycoprotein (P-gp) as well as other glycoproteins are involved. Identification of these glycoprotein markers is critical for understanding the resistance mechanism and developing therapeutics.

Methods: In this study, we report our comparative and quantitative site- and structure-specific N-glycoproteomics study of MCF-7/ADR cancer stem cells (CSCs) vs. MCF-7/ADR cells. With zic-HILIC enrichment, isotopic diethyl labeling, RPLC-MS/MS (HCD) analysis and GPSeeker DB search, differentially expressed N-glycosylation was quantitatively characterized at the intact N-glycopeptide level.

Results: 4016 intact N-glycopeptides were identified with spectrum-level FDR ≤ 1%. With the criteria of ≥ 1.5 fold change and p value < 0.05, 247 intact N-glycopeptides were found differentially expressed in MCF-7/ADR CSCs as putative markers. Raw data are available via ProteomeXchange with identifier PXD013836.

Conclusions: Quantitative site- and structure-specific N-glycoproteomics characterization may help illustrate the cell stemness property.

Citing Articles

Mass spectrometry-based structure-specific glycoproteomics and biomedical applications.

Bi M, Tian Z Acta Biochim Biophys Sin (Shanghai). 2024; 56(8):1172-1183.

PMID: 39118567 PMC: 11464918. DOI: 10.3724/abbs.2024133.

-Glycoproteomics Study of Putative -Glycoprotein Biomarkers of Drug Resistance in MCF-7/ADR Cells.

Yang H, Xu F, Xiao K, Chen Y, Tian Z Phenomics. 2023; 1(6):269-284.

PMID: 36939756 PMC: 9590513. DOI: 10.1007/s43657-021-00029-8.

CDKAL1 Drives the Maintenance of Cancer Stem-Like Cells by Assembling the eIF4F Translation Initiation Complex.

Huang R, Yamamoto T, Nakata E, Ozaki T, Kurozumi K, Wei F Adv Sci (Weinh). 2023; 10(12):e2206542.

PMID: 36786012 PMC: 10131790. DOI: 10.1002/advs.202206542.

Comparative glycoproteomics study on the surface of SKOV3 IOSE80 cell lines.

Zhou Y, Cai X, Wu L, Lin N Front Chem. 2022; 10:1010642.

PMID: 36482940 PMC: 9723240. DOI: 10.3389/fchem.2022.1010642.

Aberrant N-glycolylneuraminic acid in breast MCF-7 cancer cells and cancer stem cells.

Yang W, Jiang Y, Guo Q, Tian Z, Cheng Z Front Mol Biosci. 2022; 9:1047672.

PMID: 36419929 PMC: 9676485. DOI: 10.3389/fmolb.2022.1047672.

References

Zhong H, Davis A, Ouzounova M, Carrasco R, Chen C, Breen S . A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. Cancer Res. 2016; 76(2):480-90. DOI: 10.1158/0008-5472.CAN-15-0883. View

Vizcaino J, Cote R, Csordas A, Dianes J, Fabregat A, Foster J . The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2012; 41(Database issue):D1063-9. PMC: 3531176. DOI: 10.1093/nar/gks1262. View

Martin T, Jiang W . Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma. Oncol Rep. 2013; 31(1):262-72. DOI: 10.3892/or.2013.2813. View

Ferreira J, Peixoto A, Neves M, Gaiteiro C, Reis C, Assaraf Y . Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resist Updat. 2016; 24:34-54. DOI: 10.1016/j.drup.2015.11.003. View

Chen Z, Yu Q, Hao L, Liu F, Johnson J, Tian Z . Site-specific characterization and quantitation of N-glycopeptides in PKM2 knockout breast cancer cells using DiLeu isobaric tags enabled by electron-transfer/higher-energy collision dissociation (EThcD). Analyst. 2018; 143(11):2508-2519. PMC: 5975206. DOI: 10.1039/c8an00216a. View

Prieto-Vila M, Takahashi R, Usuba W, Kohama I, Ochiya T . Drug Resistance Driven by Cancer Stem Cells and Their Niche. Int J Mol Sci. 2017; 18(12). PMC: 5751177. DOI: 10.3390/ijms18122574. View

Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim H . CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010; 120(9):3326-39. PMC: 2929722. DOI: 10.1172/JCI42550. View

Dwek R . Glycobiology: Toward Understanding the Function of Sugars. Chem Rev. 1996; 96(2):683-720. DOI: 10.1021/cr940283b. View

Hakomori S . Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996; 56(23):5309-18. View

10.

Chen Y, Li Z, Ye Y, Xu F, Niu R, Zhang H . Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride. BMC Mol Biol. 2016; 17:6. PMC: 4776391. DOI: 10.1186/s12867-016-0055-y. View

11.

Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T . Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2006; 99(1):9-17. DOI: 10.1007/s10549-006-9175-2. View

12.

Eustaquio Do Imperio G, Bloise E, Javam M, Lye P, Constantinof A, Dunk C . Chorioamnionitis Induces a Specific Signature of Placental ABC Transporters Associated with an Increase of miR-331-5p in the Human Preterm Placenta. Cell Physiol Biochem. 2018; 45(2):591-604. PMC: 7202864. DOI: 10.1159/000487100. View

13.

Xiao K, Tian Z . GPSeeker Enables Quantitative Structural N-Glycoproteomics for Site- and Structure-Specific Characterization of Differentially Expressed N-Glycosylation in Hepatocellular Carcinoma. J Proteome Res. 2019; 18(7):2885-2895. DOI: 10.1021/acs.jproteome.9b00191. View

14.

Koehler C, Arntzen M, Thiede B . The impact of carbon-13 and deuterium on relative quantification of proteins using stable isotope diethyl labeling. Rapid Commun Mass Spectrom. 2015; 29(9):830-6. DOI: 10.1002/rcm.7170. View

15.

Fukumoto H, Nishio K, Ohta S, Hanai N, Saijo N . Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody. Int J Cancer. 1996; 67(5):676-80. DOI: 10.1002/(SICI)1097-0215(19960904)67:5<676::AID-IJC14>3.0.CO;2-3. View

16.

Ranji P, Salmani Kesejini T, Saeedikhoo S, Alizadeh A . Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance. Tumour Biol. 2016; 37(10):13059-13075. DOI: 10.1007/s13277-016-5294-5. View

17.

Kool M, de Haas M, Scheffer G, Scheper R, Van Eijk M, Juijn J . Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997; 57(16):3537-47. View

18.

Liu M, Zhang W, Tang W, Wang Y, Zhao X, Wang X . Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells. Tumour Biol. 2015; 37(2):1919-31. DOI: 10.1007/s13277-015-3997-7. View

19.

Guler G, Balci S, Costinean S, Ussakli C, Irkkan C, Suren D . Stem cell-related markers in primary breast cancers and associated metastatic lesions. Mod Pathol. 2012; 25(7):949-55. PMC: 3400504. DOI: 10.1038/modpathol.2012.37. View

20.

Liu Y, Peng H, Zhang J . Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol Pharmacol. 2005; 68(2):430-8. DOI: 10.1124/mol.105.011015. View